Cargando…

Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis

Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuan, Zhu, Shuai, Li, Yanhong, Lu, Qian, Zhang, Qiuyi, Su, Linchong, Zhang, Qiuping, Zhao, Yi, Luo, Yubin, Liu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664606/
https://www.ncbi.nlm.nih.gov/pubmed/33199983
http://dx.doi.org/10.3892/etm.2020.9387
_version_ 1783609866019930112
author Yang, Yuan
Zhu, Shuai
Li, Yanhong
Lu, Qian
Zhang, Qiuyi
Su, Linchong
Zhang, Qiuping
Zhao, Yi
Luo, Yubin
Liu, Yi
author_facet Yang, Yuan
Zhu, Shuai
Li, Yanhong
Lu, Qian
Zhang, Qiuyi
Su, Linchong
Zhang, Qiuping
Zhao, Yi
Luo, Yubin
Liu, Yi
author_sort Yang, Yuan
collection PubMed
description Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic effect of human umbilical cord derived-MSCs (UC-MSCs) on bleomycin-induced SSc in mice and explore the potential underlying mechanism. The murine SSc model was established by daily subcutaneous injection of bleomycin for 4 weeks, followed with two UC-MSC infusions every 7 days. Skin fibrosis was assessed by H&E and Masson staining. Flow cytometry was used to determine IL-17A, IFN-γ, tumor necrosis factor-β, IL-10 and IL-12 levels in serum samples and T cell subsets in murine spleen. Additionally, gene expression levels of cytokines and fibrosis markers in skin samples were measured by reverse transcription-quantitative PCR. Immunofluorescence staining was performed to track UC-MSC localization and lymphocyte cell infiltration in vivo. UC-MSC treatment exerted an anti-fibrotic role in bleomycin-induced SSc mice, as confirmed by histological improvement, decreased collagen synthesis, and reduced collagen-1α1, collagen-1α2, fibronectin-1 and α-smooth muscle actin gene expression levels. The results indicated that UC-MSC treatment only had a limited systematic effect on cytokine production in serum samples and T cell activation in the spleen. By contrast, T helper (Th)17 cell infiltration and activation in skin were efficiently inhibited after UC-MSC infusion, as evidenced by the decreased IL-17A and retinoic acid-related orphan receptor γt gene expression as well as IL-17A production. UC-MSC administration significantly ameliorated bleomycin-induced skin fibrosis and collagen formation primarily by eliminating local inflammation and Th17 cell activation in the skin; however, the systemic inhibitory effect of UM-MSCs on cytokines was less profound.
format Online
Article
Text
id pubmed-7664606
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-76646062020-11-15 Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis Yang, Yuan Zhu, Shuai Li, Yanhong Lu, Qian Zhang, Qiuyi Su, Linchong Zhang, Qiuping Zhao, Yi Luo, Yubin Liu, Yi Exp Ther Med Articles Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic effect of human umbilical cord derived-MSCs (UC-MSCs) on bleomycin-induced SSc in mice and explore the potential underlying mechanism. The murine SSc model was established by daily subcutaneous injection of bleomycin for 4 weeks, followed with two UC-MSC infusions every 7 days. Skin fibrosis was assessed by H&E and Masson staining. Flow cytometry was used to determine IL-17A, IFN-γ, tumor necrosis factor-β, IL-10 and IL-12 levels in serum samples and T cell subsets in murine spleen. Additionally, gene expression levels of cytokines and fibrosis markers in skin samples were measured by reverse transcription-quantitative PCR. Immunofluorescence staining was performed to track UC-MSC localization and lymphocyte cell infiltration in vivo. UC-MSC treatment exerted an anti-fibrotic role in bleomycin-induced SSc mice, as confirmed by histological improvement, decreased collagen synthesis, and reduced collagen-1α1, collagen-1α2, fibronectin-1 and α-smooth muscle actin gene expression levels. The results indicated that UC-MSC treatment only had a limited systematic effect on cytokine production in serum samples and T cell activation in the spleen. By contrast, T helper (Th)17 cell infiltration and activation in skin were efficiently inhibited after UC-MSC infusion, as evidenced by the decreased IL-17A and retinoic acid-related orphan receptor γt gene expression as well as IL-17A production. UC-MSC administration significantly ameliorated bleomycin-induced skin fibrosis and collagen formation primarily by eliminating local inflammation and Th17 cell activation in the skin; however, the systemic inhibitory effect of UM-MSCs on cytokines was less profound. D.A. Spandidos 2020-12 2020-10-27 /pmc/articles/PMC7664606/ /pubmed/33199983 http://dx.doi.org/10.3892/etm.2020.9387 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yang, Yuan
Zhu, Shuai
Li, Yanhong
Lu, Qian
Zhang, Qiuyi
Su, Linchong
Zhang, Qiuping
Zhao, Yi
Luo, Yubin
Liu, Yi
Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title_full Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title_fullStr Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title_full_unstemmed Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title_short Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
title_sort human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664606/
https://www.ncbi.nlm.nih.gov/pubmed/33199983
http://dx.doi.org/10.3892/etm.2020.9387
work_keys_str_mv AT yangyuan humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT zhushuai humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT liyanhong humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT luqian humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT zhangqiuyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT sulinchong humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT zhangqiuping humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT zhaoyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT luoyubin humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis
AT liuyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis